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Three series of Nr-substituted adenosine derivatives were synthesized, having in common an unbranched 
alkyl chain with lengths varying from 2 to 12 methylene units, but differing in their a~-alkyl substituents: 
Nr-n-alkyladenosines (I), Nr-co-amino-alkyladenosines (II) and ct og,di-(adenosin-Nr-yl)alkanes (III). The 
compounds of the latter series combine two functional groups in one molecule. Al-receptor affinity of these 
compounds was measured as inhibition of [3H]PIA binding to calf brain membranes. With relatively short 
chain lengths, compounds in series I are the most potent. In this series, optimum acitivity is reached with 
Nr-n-pentyladenosine (Ki = 0.50 nM). With short chain lengths, compounds in series II and III are 6-20-fold 
less potent han their congeners in series I. The potency order however is reversed with higher chain lengths. 
While affinity in series II and III increases strongly, reaching an optimum with the nonyl derivatives, affinity 
in series I decreases sharply with alkyl chains larger than 8 methylene units. Highest affinity is found with 
9-amino-nonyladenosine (Ki=0.32 nM). In general, the to-aminoalkyl derivatives are somewhat more po- 
tent than the corresponding di-adenosinyl derivatives. Implications for the possible topography of the N 6 
region of the A~-receptor and the area further emoved from N 6 are dicussed. 
Adenosine A~-receptor; N 6 region 
1. INTRODUCTION 
Adenosine has numerous physiological actions, 
including vasodilation and hypotension, muscle 
relaxant and central depressant effects and inhibi- 
tion of platelet aggregation [1]. These actions are 
thought to be mediated via membrane bound 
receptors. Presently, the existence of two 
adenosine receptor subtypes, AI and A2, is general- 
ly accepted. At the A~-receptor, Nr-R-l-phenyl-2 - 
propyladenosine (R-PIA) is more potent than 
5'-N-ethylcarboxamideadenosine (NECA). There 
is a marked stereoselectivity for the R- and S- 
stereoisomers of PIA: at the Al-receptor, R-PIA is 
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at least 10-fold more potent than S-PIA. At the 
A2-receptor, NECA is more potent than R-PIA 
and stereoselectivity for the isomers of P IA is less 
than 10-fold [2]. 
Substitutions at or modifications of the adenine 
ring or the ribose moiety in adenosine usually lead 
to compounds with less activity, or no activity at 
all. The one exception is substitution at N 6, which 
can enhance affinity at Al-receptors greatly [3]. 
Consequently, the search for new adenosine 
derivatives as ligands for the Al-receptor has been 
focussed mainly on the N 6 region. A general model 
for this region was introduced by Kusachi et al. [4]. 
The N 6 region was explored extensively and 
systematically with a number of Nr-substituted 
adenosine derivatives in three studies [5-7]. In 
these studies chirality at C2 of the Nr-substituent, 
a prominent feature of the Al-receptor, is heavily 
emphasized. Less is known about points of interac- 
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Fig. 1. Synthesized compounds. I, R = H; II, R = NH2; 
III, R = adenosin-N6-yl, n = 2-12. 
tion more remote from the N 6 region, with the ex- 
ception of the studies of Jacobson et al. [8,9], 
using the functionalized congener approach. 
In order to extend the knowledge of possible 
binding sites further removed from the N 6 region, 
we synthesized three series of N6-substituted 
adenosine derivatives, having in common an un- 
branched alkyl chain with lengths varying from 2 
to 12 methylene units, but differing in their w-alkyl 
substituents (fig.l). R = H yields N6-n - 
alkyladenosines (I) and R = NH2 yields N6-w -
aminoalkyladenosines (II). The compounds of the 
third series, cr,a~-di(adenosin-N6-yl) alkanes (III), 
have a second adenosine molecule and thus com- 
bine two functional groups in one molecule. 
Portoghese and co-workers [10] have introduced 
the term bivalent ligands for this type of com- 
pounds. It describes molecules that contain two 
pharmacophores, joined by a spacer arm. Such 
molecules might bind with both pharmacophores 
to two different recognition sites simultaneously 
[10]. In opioid receptor esearch, this approach as 
led to the development of bimorphinans, potent 
and selective ~c-receptor antagonists [11]. 
2. MATERIALS AND METHODS 
Compounds were synthesized according to the 
well established method of Fleysher et al. [12]. 
Briefly stated, 6-chloropurineriboside (6-CPR) was 
refluxed for 2 -6  h in ethanol with the appropriate 
alkylamine to give N6-substituted adenosines. 
Triethylamine or excess of the alkylamine were 
used as proton scavengers. In the synthesis of II 
and II I ,  ce,oJ-diamino alkanes were used. With a 
5-10-fold molar excess of the diamine, almost ex- 
clusively II was formed. With a slight excess of 
6-CPR, predominantly II I  was formed. Com- 
pounds were purified by extraction and/or 
recrystallization. Purity was checked by TLC. 
Structures were confirmed by 300 MHz NMR 
spectroscopy. 
N6-(2-Aminoethyl)adenosine, N6-(4-aminobu - 
tyl)adenosine, 1,2-di(adenosin-N6-yl)ethane and 
1,4-di(adenosin-N6-yl)butane were gifts of Dr J. 
Zemlicka, Michigan Cancer Foundation, Detroit. 
Adenosine deaminase was from Boehringer, 
Mannheim, FRG. 8-Phenyltheophylline was from 
Janssen Chimica, Beerse, Belgium. [3H]PIA 
(40 Ci/mmol) was from Amersham, Buckingham- 
shire, England. 
2.1. Preparation of membranes 
Calf brain (approx. 300 g), obtained from a 
local slaughterhouse, was placed in 5 mM Hepes- 
Tris (pH 7.4) (buffer A) within 30 min of 
slaughter. Cerebral cortex was dissected, 
disrupted, diluted to a total volume of 2500 ml 
with buffer A and centrifuged at 10000 × g for 
10 min. The supernatant was centrifuged at 30000 
x g for 45 min. The P2 fraction was washed in 
600 ml of buffer A and recentrifuged at 30000 x 
g for 45 min. The pellet was resuspended in 55 ml 
of buffer A, incubated with 200 IU of adenosine 
deaminase for 30 min at 37°C and stored in liquid 
nitrogen. Protein was assayed according to the 
method of Lowry et al. [13]. 
2.2. Binding assay 
[3H]PIA binding assays were performed in 
50 mM Tris-HCl (pH 7.4) (buffer B) in a final 
volume of 400/zl. The standard assay contained 
-40/~g membrane protein and 0.3 nM [3H]PIA. 
Incubations were carried out in duplicate for 
120 min at 25°C and were terminated by diluting 
the samples with 1 ml ice-cold buffer B, followed 
by rapid filtration through Whatman GF/C  glass 
fiber filters. Subsequently, tubes were washed with 
1 ml buffer and filters were washed twice with 3 ml 
buffer B. Filters were dried for 45 min at 60°C, 
3.5 ml of scintillation fluid (LKB OptiPhase MP) 
was added and radioactivity was determined in an 
LKB 1214 Rackbeta liquid scintillation counter. 
Solutions of N6-substituted adenosines were made 
in DMSO and were diluted with buffer to a final 
DMSO concentration of 1 °7o. Non-specific binding 
was determined in the presence of 5 × 10-6M 
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8-phenyltheophylline. Ki values were calculated 
with a computer program based on the law of 
mass-action [14], using a Kd for [3H]PIA of 
0.16 nM (unpublished). 
3. RESULTS AND DISCUSSION 
A~-receptor affinity [15] was determined in a 
binding assay using calf cerebral cortical mem- 
branes and [3H]PIA as the radioligand. 
In table 1, Ki values for the various compounds 
tested are listed. In fig.2, pKi values are 
represented as a function of spacer length. 
Within the N6-n-alkyladenosine series (I), com- 
pounds with relatively short N6-substituents are the 
most potent inhibitors of [3H]PIA binding. This is 
in agreement with the assumption of Daly that 
hydrophobic interactions play an important role in 
binding to the N 6 region [5]. 
In contrast with our results however, Daly 
(measuring [3H]CHA displacement in rat brain 
membranes) observed optimum activity with N6-n -
propyl and N6-n-butyladenosine. With N6-n-pentyl 
and N6-n-hexyladenosine, a sharp decline in activi- 
ty was seen. In our assay, potency in the n- 
alkyladenosine series remains high with chain 
lengths up to 8 methylene units, and optimum ac- 
tivity is found with N6-n-pentyladenosine (Ki = 
0.50 nM). This may be attributed to species dif- 
Table 1 
Ki values of N6-substituted adenosine derivatives (nM, 
+_ SE) for displacement of [3H]PIA in calf brain 
I. N6-alkyl - II. N6-(a, - III. o6a~-di- 
adenosines aminoalkyl)- (adenosinyl)- 
adenosines alkanes 
2 3.9 _+ 0.3 38 __ 3 76 +_ 13 
3 1.1 _+ 0.1 9.1 _+ 1.2 18 _+ 1 
4 1.5 _+ 0.1 8.9 _+ 0.7 23 _+ 2 
5 0.50 _+ 0.04 3.7 _+ 0.4 4.0 _+ 0.9 
6 1.8 _+ 0.2 0.97 +_ 0.10 2.0 _+ 0.2 
8 1.9 _+ 0.2 0.50 + 0.05 1.3 _+ 0.1 
9 8.1 _+ 0.7 0.32 _+ 0.03 0.70 _+ 0.05 
l0 21 4- 2 0.51 __ 0.04 2.0 +_ 0.1 
II 71_+5 - - 
12 147 _+ 34 1.7 _+ 0.2 5.6 _+ 0.4 
Values are means of 3 experiments, n = number of 
methylene units 
10-  
t 
pk~ 
n 
Fig.2. Plot of pKi values of N6-substituted adenosine 
derivatives ([3H]PIA binding to calf brain membranes) 
versus chain length. (n) N6_n_alkyladenosines, (o) 
N6~-amino-alkyladenosines, (o) o~,~-di-(adenosin- 
N6-yl) alkanes; n = number of methylene units. 
ferences between A~-receptors in rat brain and in 
calf brain. Such differences are especially clear in 
the case of xanthine adenosine antagonists, which 
are much more potent in bovine brain than in rat 
brain [16]. 
Our results show that also for agonist ligands, 
there are significant differences in binding to 
Al-receptors of rat brain and calf brain, respec- 
tively. 
With the compounds of series II and III with 
n = 2-4,  a 6-20-fold decrease in affinity is seen, 
as compared to the affinities of the corresponding 
compounds of series I. Again, this may be com- 
pared to the findings of Daly. When various polar 
terminal groups were attached to N6-ethyl - 
adenosine, the resulting compounds all had less 
affinity for the Al-receptor than N6-ethyladeno - 
sine itself. N6-2-Aminoethyladenosine was the least 
potent, with a 17-fold decrease in affinity [5]. Ap- 
parently, hydrophilicity is not tolerated very well 
in the area close to N 6. 
Differences in Ki between series II, with a small 
and positively charged terminal amino group, and 
series III, with a bulky adenosine substituent, are 
quite small, 2-4-fold at the most, which seems to 
indicate that steric hindrance does not play an im- 
portant role here. 
With increasing chain length, the order of poten- 
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cy is reversed. The N%n-alkyladenosines with 
N6-substituents larger than 8 carbon atoms steadily 
lose potency, while the compounds in series II and 
II I  show a rapid increase in affinity, with an op- 
t imum of nine methylene units in both series. 
Thus, N6-9-amino-nonyladenosine is very potent 
(Ki = 0.32 nM) and has 25-fold higher affinity 
than N6-n-nonyladenosine. N6-12-Aminododecyl - 
adenosine has even 86-fold higher affinity than 
N~-n-dodecyladenosine. This reversal of potency 
order with increasing chain length is best explained 
if it is assumed that the area further removed from 
N ~ is essentially hydrophilic in nature. This would 
be unfavourable for the adenosine analogs with a 
long and lipophilic alkyl chain. An accessory site 
for a relatively polar terminal group like an amine 
or adenosine would overcome this unfavourable 
effect, yielding the more potent compounds of 
series II and II I  with chain lengths from 8 to 12 
methylene units. Jacobson observed similar in- 
creases in potency with a terminal amine attached 
to functionalized congeners of N6-phenyladenosine 
[8] and xanthine adenosine antagonists [17]. 
Whether, as was suggested, this can be ascribed to 
an ionic interaction of the positively charged amine 
with a negatively charged part of the receptor 
seems doubtful, since the affinities of the non- 
ionic compounds in series II I  constantly parallel 
the affinities of the charged amines of series II. 
These close similarities between series II and III 
also show that it is unlikely that the a,a:- 
di(adenosin-N6-yl) alkanes actually bridge two 
receptor sites. In that case, a different profile 
would be expected for the interaction of an 
adenosine moiety to a second receptor site and the 
binding of an amino group to a less specific ac- 
cessory site. Moreover, a bivalent ligand would be 
expected to bind more strongly, which is evidently 
not the case for these compounds. 
Since lipophilic substituents play an important 
role in the binding of N6-substituted adenosine 
analogs, our choice for a distinctly lipophilic 
spacer arm seemed justified. However, it is con- 
ceivable that via these strong, hydrophobic interac- 
tions in the N 6 region, the spacer arm becomes 
orientated in such a way that the interaction of the 
terminal adenosine group with a second receptor 
site is actually hampered. Therefore, it could be of 
interest o synthesize bifunctional molecules with a 
less lipophilic spacer arm, in order to investigate if
two adenosine receptors can actually be bridged by 
one bivalent ligand. A prerequisite, however, is 
that binding sites are organized in a regular 
recognition pattern, situated on oligomeric 
subunits. It is likely that this is the case for the 
earlier mentioned x-opioid receptors [l 1], but 
whether this is also the case for adenosine recep- 
tors remains to be shown. 
In conclusion, the picture that arises from this 
work is a hydrophobic region near N 6, developing 
into a hydrophilic area further removed from N 6, 
with ample space to accommodate bulky groups 
like adenosine. Speculatively, these qualifications 
would be compatible with a situation in which N 6 
is pointed away from the receptor, directed into 
the extracellular space, which of course meets both 
the requirements concerning hydrophilicity and 
space. 
Interestingly, something similar is seen with 
several enzymes that have binding sites for 
adenosine-containing coenzymes. The structures 
of some of these enzyme-coenzyme complexes, e.g. 
parahydroxybenzoate-hydroxylase with FAD and 
dihydrofolatereductase with NADP are known 
[18,19]. When these structures are examined with 
the aid of molecular graphics, it is evident hat the 
domain where the N 6 in the adenosine moiety of 
the coenzyme is binding is invariably on the sur- 
face of the protein, with N ~ pointing outwards (R. 
Wieringa and H. van Vlijmen, personal com- 
munication). 
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